Nektar Therapeutics
NKTR
40.26
+0.35
+0.88%
Nektar Therapeutics
US · NKTR
#3017 by market cap
Listed 1970
40.26
+0.35
+0.88%
Live - 5344 symbols - heartbeat 371s ago
· 2026-10-08 06:54
Pre-market
39.35
-2.26%
After-hours
40.00
-0.65%
Overnight
40.20
-0.15%
- Market cap
- 1.37B
- P/E (TTM)i
- -6.58
- P/Bi
- 1.52
- EPSi
- -9.73
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on NKTR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.9 percentage points.
Institutional ownership
- Held by institutions
- 106.77% +0.87pp
- Institutions
- 267 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund51.39%
Hedge Fund42.60%
Public Company4.98%
VC/PE Fund4.15%
Private Company2.41%
Sovereign Wealth Fund0.64%
Government Pension Fund0.41%
Individual/Insider0.37%
Insurance Company0.16%
Top holders as of 2026-06-30
FMR
14.84% · 5.07M sh
Two Seas Capital LP
9.80% · 3.35M sh
BlackRock
8.62% · 2.94M sh
BVF Partners L.P.
7.00% · 2.39M sh
Vanguard Capital Management, LLC
5.09% · 1.74M sh
Two Sigma Investments, LP
3.52% · 1.20M sh
Vestal Point Capital, LP
2.93% · 1.00M sh
State Street Global Advisors
2.66% · 909.68K sh
Geode Capital Management, LLC
2.58% · 881.31K sh
Morgan Stanley
2.41% · 824.20K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Howard Robin | Chief Executive Officer | 0.16% |
| R. Greer | Independent Director | 0.06% |
| Roy Whitfield | Lead Independent Director | 0.06% |
| Robert Chess | Independent Chairperson | 0.05% |
| Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | 0.03% |
| Jeffrey Ajer | Independent Director | 0.01% |
| Diana Brainard | Independent Director | 0.01% |
| Mark Wilson | Chief Legal Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-22 | Robert Chess | Independent Chairperson | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Robert Chess | Independent Chairperson | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | R. Greer | Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | R. Greer | Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | Roy Whitfield | Lead Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Roy Whitfield | Lead Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | Jeffrey Ajer | Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Jeffrey Ajer | Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-09-22 | Diana Brainard | Independent Director | Other Acquisition | +2,000 | -- |
| 2026-09-22 | Diana Brainard | Independent Director | Other Derivative Acquisition | +4,000 | $57.66 |
| 2026-08-17 | Howard Robin | Chief Executive Officer | Open Market Disposition | -418 | $71.98 |
| 2026-08-17 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Open Market Disposition | -186 | $71.98 |
| 2026-07-23 | Howard Robin | Chief Executive Officer | Other Derivative Acquisition | +57,200 | $15.15 |
| 2026-07-23 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Other Derivative Acquisition | +16,500 | $15.15 |
| 2026-06-29 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Automatic Disposition | -5,681 | $70.00 |
| 2026-06-16 | Howard Robin | Chief Executive Officer | Automatic Disposition | -20,000 | $59.97–61.65 |
| 2026-06-16 | Howard Robin | Chief Executive Officer | Intent to Sell (Form 144) | -10,000 | $60.27 |
| 2026-06-15 | Howard Robin | Chief Executive Officer | Intent to Sell (Form 144) | -10,000 | $60.96 |
| 2026-06-14 | Jonathan Zalevsky | Senior VP & Chief Research and Development Officer | Automatic Disposition | -5,538 | $60.71 |
| 2026-05-18 | Howard Robin | Chief Executive Officer | Open Market Disposition | -444 | $65.51 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:54:04 · For reference only, not investment advice and not tailored to your situation.